Ivana Magovčević-Liebisch, Vigil

Vig­il rais­es $90M in neu­ro­science 're­nais­sance.' Is an IPO around the cor­ner?

A cou­ple of years ago, Am­gen joined Big Phar­ma’s mass ex­o­dus from neu­ro­science, as ex­ecs ei­ther aban­doned or trimmed back their pro­grams in the field.

Now, a small Cam­bridge, MA-based biotech is sprint­ing to­ward the clin­ic with two of Am­gen’s old TREM2 as­sets, and in­vestors are putting down $90 mil­lion ahead of what they be­lieve could be neu­ro­science’s big come­back.

Vig­il Neu­ro­science un­veiled a meaty Se­ries B round led by Arie Bellde­grun’s Vi­da Ven­tures on Wednes­day morn­ing, bring­ing the biotech’s to­tal raise to $140 mil­lion. The com­pa­ny launched less than a year ago with a $50 mil­lion Se­ries A round — and CEO Ivana Magov­če­vić-Liebisch says their next fi­nanc­ing will like­ly take place on the pub­lic mar­kets.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.